Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

CLTX-CAR T cells exhibit preclinical activity and move on to a clinical trial

Key clinical point: Chlorotoxin (CLTX)-directed chimeric antigen receptor (CAR) T cells have proved active against glioblastoma tumor cells with minimal off-target effects.

Major finding: Intracranial administration of CLTX-CAR T cells controlled tumor growth and extended survival in mouse models of glioblastoma.

Study details: A preclinical study of CLTX-directed CAR T cells.

Disclosures: The study was funded by the Ben and Catherine Ivy Foundation and the National Institutes of Health. Two authors reported financial affiliations with Mustang Bio.


Wang D et al. Sci Transl Med. 2020 Mar 4. doi: 10.1126/scitranslmed.aaw2672.